Abstract: The present invention relates to vasodilators for use in the treatment of a retinal ischemic disorder in a mammal by reducing the retinal ischemic damage for both the photoreceptors (A-wave amplitude) and the Muller and ON-bipolar cells (B-wave amplitude) by at least 10%, when measured by Electroretinography in the mammal compared to the ET-1 induced ischemia alone, at day 3 and at day 21 after the ischemic event and the vasodilator is first applied. The vasodilator may preferably be selected from the group consisting of Calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and calcitonin.

Abstract: A method and device for performing direct quantitative real time PCR in a crude sample, wherein said sample is subjected to a centrifugal force sufficient to separate components of the sample into a supernatant and a pellet, and wherein said at least one light source and said at least one detector are positioned so that the excitation light impinges on the sample in a position above said pellet, and said detector detects light emitted from a position above said pellet.

Abstract: A method and device for performing direct quantitative real time PCR in a crude sample (200), wherein said sample is subjected to a centrifugal force sufficient to separate components of the sample into a supernatant and a pellet, and wherein at least one light source (204) and at least one detector (205) are positioned so that the excitation light impinges on the sample in a position above said pellet, and said detector detects light emitted from a position above said pellet.

Abstract: A method and device for performing direct quantitative real time PCR in a crude sample (200), wherein said sample is subjected to a centrifugal force sufficient to separate components of the sample into a supernatant and a pellet, and wherein at least one light source (204) and at least one detector (205) are positioned so that the excitation light impinges on the sample in a position above said pellet, and said detector detects light emitted from a position above said pellet.

Abstract: The invention relates to the use of at least on inhibitor selected from the group consisting of raf-, protein kinase C (PKC)-, MEK1/2-, or ERK1/2-inhibitors, for the manufacturing of a medicament to be administrated from 1 up to 12 hours after initiation of an ischemic disease.

Abstract: The invention relates to the use of at least on inhibitor selected from the group consisting of raf-, protein kinase C(PKC)-, MEK1/2-, or ERK1/2-inhibitors, for the manufacturing of a medicament to be administrated from 1 up to 12 hours after initiation of an ischemic disease.

Abstract: A method of preventing or alleviating renal disorders by administering to a human or an animal in need thereof a pharmaceutical composition comprising an effective amount amount of at least one specific isomer of inositol trisphosphate sufficient to obtain said prevention or alleviation.

Abstract: The present invention relates to the use of inositoltrisphosphate (IP.sub.3) for the preparing of a medicament effective as a neuropeptide Y- (NPY-) antagonist and to a pharmaceutical composition comprising at least one specific isomer of IP.sub.3 and a pharmaceutically active compound effective in the cardiovascular, renal and/or cerebral area.

Abstract: A method of preventing or alleviating certain conditions by administering to a human or an animal a pharmaceutical composition comprising an amount of at least one specific isomer of inositol trisphosphate sufficient to obtain said prevention or alleviation.